Dr. Harrison and colleagues reply

摘要

Diamantidis questions similarities in the proportion of progression events between patients who received best available therapy and patients who received ruxolitinib. These similarities are largely attributable to differing definitions of progression - an increase in spleen volume of 25% or more from the on-study nadir in COMFORT-II versus an increase in spleen volume of 25% or more from baseline in CQMFQRT-I. For example, a patient in COMFORT-II with a starting spleen volume of 2000 cm~3 and a study nadir of 500 cm~3 would have disease progression with a spleen volume of 625 cm~3, but he or she would not have disease progression until 2500 cm~3 in COMFORT-I. At week 48, as shown in Figure 1, the majority of rux-olitinib-treated patients maintained significant reductions in spleen volume, regardless of JAK2 V617F mutation status.